It is among the largest universities in East and Central Africa, with a student population of over 30,000 undergraduate and 3,000 postgraduate students. Makerere consists of 22 faculties, institutes and schools and is an active center of research. While some faculties including Medicine were founded as early as 1924, Makerere was established as the University of East Africa in 1963, and became an independent national university of the Republic of Uganda in 1970. For more information visit: www.mak.ac.ug
About Upstream Biosciences, Inc.
Upstream Biosciences is focused on developing and commercializing drug candidates to treat tropical diseases, including leishmaniasis, trypanosomiasis, and malaria. Caused by parasites that have developed resistance to available treatments, these diseases afflict millions of people living in the tropics with death, illness, malnourishment and economic hardship. Upstream's drug candidates are generated using its proprietary computer-assisted drug discovery process. The Company's lead drug candidates have demonstrated anti-parasitic efficacy in vitro and positive safety data in animals.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking statements, as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) the Company's proprietary drugs may treat livestock and humans for Trypanosomiasis; (ii) animal efficacy testing may lead to the selection of a drug candidate to treat Trypanosomiasis in livestock followed by a human treatment; (iii) the results of animal efficacy testing may allow the Company to take an important step towards development its first drug for a veterinary application in Africa; (iv) the Company's treatment for Trypanosomiasis could have a huge economic impact on Africa; and (v) an effective treatment for Trypanosomiasis in livestock could significantly increase the production of meat, dairy, and agricultural products across sub-Saharan Africa. Actual results could differ from those projected in any forward-looking statements due to numerous factors.
